NCT06521567 2025-11-12
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
Phase 1/2 Active not recruiting
GlaxoSmithKline
Valent Technologies, LLC
Eureka Therapeutics Inc.
Bayer
TRPHARM
Novartis